Roots Analysis has done a detailed study on Neoantigen Targeted Therapies, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/neoantigen-targ...

Key Market Insights
 Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration
 Several molecules are in early stages of clinical development; based on delivery strategies, variety of vaccines and immunotherapies have been established for targeting personalized and shared antigens
 Over the years, more than 6,000 patents related to neoantigens and affiliated therapies have been granted / filed; this is indicative of the heightened pace of research in this field
 Both industry and academic players are contributing to the innovation, which is evident across published scientific literature focused on multiple targeted therapies for a myriad of cancer indications
 Several investors, having realized the untapped opportunity within this emerging segment of cancer immunotherapy, have invested over USD 7 billion across 150 instances in the period between 2014 and 2019
 The increasing traction in this field is also reflected in the partnership activity; deals inked in the recent past focused on a diverse range of therapies, involving both international and indigenous stakeholders
 The market will receive the required impetus after approval of the first neoantigen targeted therapy; the future growth is likely to be driven by the successful clinical outcomes of the late-stage molecules
 In fact, opinions from industry experts confirm the vast potential of this segment of cancer immunotherapy, capable of targeting personalized / off-the-shelf tumour antigens with multiple types of vaccines and therapies

For more information, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targ...

Contact Details:
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]